Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
Katie G YoungKatherine G YoungAnand T N NairRhian HopkinsAndrew P McGovernEram HaiderPiyumanga KarunaratneLouise DonnellyBilal A MateenNaveed SattarRury R HolmanJack BowdenAndrew T HattersleyEwan R PearsonAngus G JonesBeverley M ShieldsTrevelyan J McKinleyRaphael Sonabendnull nullPublished in: Diabetologia (2024)
Precision medicine approaches can facilitate effective individualised treatment choice between SGLT2i and GLP1-RA therapies, and the use of routinely collected clinical features for treatment selection could support low-cost deployment in many countries.